Plegridy: a new disease-modifying therapy approved for the treatment of RRMS
- Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis. Market Watch. Aug 15, 2014. http://www.marketwatch.com/story/biogen-idecs-plegridypeginterferon-beta-1a-approved-in-the-us-for-the-treatment-of-multiple-sclerosis-2014-08-15-181594426. Accessed August 16, 2014.
- Plegridy prescribing information. August 2014. http://www.plegridy.com/pdfs/plegridy-prescribing-information.pdf. Accessed August 16, 2014.
- Kieseier BC1, Calabresi PA. PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis. CNS Drugs. 2012;26(3):205-214.
- Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13(7):657-665.